We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Evaluation of Human Zinc Absorption From Wheat-based Meals

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01775319
Recruitment Status : Completed
First Posted : January 24, 2013
Last Update Posted : April 14, 2016
Sponsor:
Collaborator:
HarvestPlus
Information provided by (Responsible Party):
Prof. Michael B. Zimmermann, Swiss Federal Institute of Technology

Brief Summary:

Study part 1 and 2 Assessment of Zn absorption from regular and biofortified wheat: stable isotope absorption studies in women of childbearing age consuming test meals prepared from either the biofortified Zn wheat, regular wheat or post-harvest fortified wheat at two different extraction rates.

Study part 3 Assessment of Zn absorption from intrinsically and extrinsically labeled wheat: stable isotope absorption studies in women of childbearing age, or men, consuming test meals prepared from either intrinsically labeled Zn biofortified wheat, regular wheat or post-harvest fortified wheat extrinsically labeled immediately before consumption.


Condition or disease Intervention/treatment
Zinc Deficiency Dietary Supplement: Biofortified wheat Dietary Supplement: Fortified wheat Dietary Supplement: Placebo

Detailed Description:

The overall goal of study part 1 and 2 is to evaluate and compare the fractional and absolute Zn absorption from biofortified wheat cultivar (60 ppm Zn) to regular wheat (28 ppm Zn) and to post harvest fortified wheat (60 ppm Zn) for a total of 3 test meals per study. The studies will be conducted with products based on wheat with high extraction rate (study part 1) and medium extraction rate (study part 2) in two separate groups of women of childbearing age.

The goal of study part 3 is to investigate the difference of absorption measurements between intrinsically and extrinsically labeled biofortified wheat. The label of the test meals will have the same nature as the fortificant itself (extrinsic vs intrinsic), for a total of 3 test meals.


Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 54 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Single (Participant)
Primary Purpose: Basic Science
Official Title: Evaluation of Human Zinc Absorption From Wheat-based Meals
Study Start Date : February 2013
Primary Completion Date : March 2014
Study Completion Date : March 2014

Arm Intervention/treatment
Active Comparator: Biofortified wheat
Biofortified wheat
Dietary Supplement: Biofortified wheat
Extrinsic label 67Zn (ZnSO4) 0.2mg 70Zn added to the IV dose
Other Name: Esperia
Placebo Comparator: Control wheat
Control wheat with low level of Zn
Dietary Supplement: Placebo
Active Comparator: Fortified wheat
Wheat fortified before consumption
Dietary Supplement: Fortified wheat
Extrinsic label 67Zn (ZnSO4) 0.2mg 70Zn added to the IV dose



Primary Outcome Measures :
  1. Fractional zinc absorption from different wheat-based test meals [ Time Frame: 3 months ]
    Fractional zinc absorption (in %) will be assessed with stable isotopes of zinc using a double isotope technique.


Secondary Outcome Measures :
  1. Zn and C-reactive protein concentration in plasma [ Time Frame: 3 months ]

Other Outcome Measures:
  1. Creatinin [ Time Frame: 2 months ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 45 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Female, 18 to 45 years old (Study part 1 and 2). Female or male, 18 to 45 years old (Study part 3)
  • Body Mass Index in the range of 18.5 to 25 kg/m2
  • Signed informed consent

Exclusion Criteria:

  • Any metabolic, gastrointestinal kidney or chronic disease such as diabetes, anemia, hepatitis, hypertension, cancer or cardiovascular diseases (according to the subjects own statement)
  • Gluten intolerance, celiac disease
  • Continuous/long-term use of medication during the whole study (except for contraceptives)
  • Vegans
  • Consumption of mineral and vitamin supplements within 2 weeks prior to 1st test meal administration
  • Smoking
  • Pregnancy (Urine pregnancy test shall be performed before each test meal administration)
  • Lactating
  • Earlier participation in a study using Zn stable isotopes or participation in any other clinical study within the last 30 days

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01775319


Sponsors and Collaborators
Swiss Federal Institute of Technology
HarvestPlus
Investigators
Principal Investigator: Diego Moretti, PhD Swiss Federal Institute of Technology

Additional Information:
Responsible Party: Prof. Michael B. Zimmermann, Prof. Dr., Swiss Federal Institute of Technology
ClinicalTrials.gov Identifier: NCT01775319     History of Changes
Other Study ID Numbers: HNL/CTC_Zn_wheat
KEK-ZH-2012-0483 ( Other Identifier: KEK-Zurich )
First Posted: January 24, 2013    Key Record Dates
Last Update Posted: April 14, 2016
Last Verified: April 2016

Keywords provided by Prof. Michael B. Zimmermann, Swiss Federal Institute of Technology:
Zinc